Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 15/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.39 |
| ▸ | CDK2 | P24941 | 15/20 | 0.39 |
| ▸ | CDK4 | P11802 | 11/20 | 0.39 |
| ▸ | CCND1 | P24385 | 11/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.36 |
| ▸ | CDK1 | P06493 | 6/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938911 | 0.80 | PPARA (0.37) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4933608 | 0.78 | CDK4 (0.34) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4940272 | 0.78 | CCNE2 (0.32) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL4930597 | 0.78 | CDK2 (0.34) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL3289678 | 0.74 | KMT2A (0.35) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL31194557 | 0.73 | CDK4 (0.33) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL29786728 | 0.70 | MAPT (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19953345 | 0.70 | MAPT (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30406179 | 0.70 | PDE5A (0.45) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL11358889 | 0.69 | ADORA2A (0.40) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-24 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | CCNE2 4262/4885CCNE1 4284/4885CDK2 1821/4885 |
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE3B | CCNE2 2825/4885CCNE1 3341/4885CDK2 1339/4885 |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | CCNE2 4232/4885CCNE1 4056/4885CDK2 2109/4885 |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | CCNE2 4556/4885CCNE1 4747/4885CDK2 3134/4885 |
| US-20090318494-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | CCNE2 3989/4885CCNE1 3799/4885CDK2 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.